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Abstract
Lung adenocarcinoma (LAC) is the most common form of lung cancer that increases in non-smokers at younger age. Altered
protein glycosylation is one of the hallmarks of malignancy, its role in cancer progression is still poorly understood. In this
study, we report mass spectrometric (MS) analysis of N-glycans released from fresh or defrosted tissue specimens from 24
patients with LAC. Comparison of cancerous versus adjacent healthy tissues revealed substantial differences in N-glycan
profiles associated with disease. The significant increase in paucimannose and high-mannose glycans with 6–9 mannose
residues and decline in the sialylated complex biantenary core fucosylated glycan with composition NeuAcGal2GlcNAc2-
Man3GlcNAc2Fuc were general features of tumors. In addition, 42 new N-glycan compositions were detected in cancerous
tissues. The prominent changes in advanced disease stages were mostly observed in core fucosylated N-glycans with
additional fucose (Fuc) residue/s and enhanced branching with non-galactosylated N-acetyl-glucosamine (GlcNAc) units.
Both of these monosaccharide types were linked preferably on the 6-antenna. Importantly, as compared with noncancerous
tissues, a number of these significant changes were clearly detectable early on in stage I. Application of N-glycan data
obtained from tissues was next assessed and validated for evaluation of small sized biopsies obtained via bronchoscopy.
In summary, observed alterations and data of newly detected N-glycans expand knowledge about the glycosylation in LAC
and may contribute to research in more tailored therapies. Moreover, the results demonstrate effectiveness of the presented
approach for utility in rapid discrimination of cancerous from healthy lung tissues.
Introduction
Lung cancer (LC) continues to be the most important cause of
cancer-associated deaths worldwide [1]. The majority of LC
represents non-small cell lung carcinoma (NSCLC) com-
prising a heterogeneous group of cancer diseases. The most
common histological type of NSCLC group is LAC with an
increasing trend in recent years and prevails in never smokers
at younger age [2]. Importantly, LAC exhibits diverse char-
acteristics as well, particularly at the molecular level [3].
Significant advances have been achieved in monitoring pro-
cesses at biomolecular levels associated with tumorigenesis
due to improvements of analytical methods [4–6]. LC studies
focused on genetic alterations resulted in identification of
genomic and proteomic signatures [7, 8]. Recent progress in
LC detection using low-dose computed tomography (LDCT)
indicates that the number of patients diagnosed in the
early stages of disease will substantially increase. Notably, the
vast majority of initial positive detections by LDCT are
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predominantly of adenocarcinoma histology [9, 10]. The
recommended treatment for patients with NSCLC at stage I is
surgery. Yet, the disease recurrence in patients following this
procedure is high within 5 years, up to 30% [6, 11]. Tissue-
based biomarkers which can categorize patient’s disease stage
after surgical treatment and identify those at high-risk for
recurrence could result in significant improvement [6]. Taking
into consideration heterogeneity of NSCLC, broader research
approaches have to be undertaken by focusing on more
relevant cancer characteristics, which could effectively dif-
ferentiate cancerous from indolent nodules of lung [12].
The posttranslational modification of proteins by glyco-
sylation is critical for a variety of biological functions and its
close association was also established in transformation of
mammalian cells and tumor progression [13]. Glycans are
generated by a set of specific enzymes, which are activated in
response to intracellular and extracellular changes [14–17].
These biomolecules are typically localized on cell surfaces
making them perfect targets for detection and characterization
of changes during tumorigenesis [16]. Application of
advanced MS technology in characterization of glycome
enabled identification of specific glycans in relation with
different disease processes including cancer [18–26]. Notable
differences were observed in glycan expression between
tumor and control tissues, as well as in expression of glyco-
sylation related genes [27]. To date, only a few studies have
been published on N-glycan analyses comparing tumor and
noncancerous tissues from patients diagnosed with LAC.
Satomaa et al. reported uniform expression of high-mannose
glycans in both normal and malignant samples of formalin-
fixed paraffin embedded (FFPE) tissues from three patient
with LAC and observed increased proportion of biantennary
core fucosylated N-glycan with both terminal GlcNAc resi-
dues [28]. The study of Ruhaak et al. on defrosted tissues
from a large number of patients with LAC, showed increased
proportion of the high-mannose and core fucosylated glycans
and decreased level of galactosylation in tumor specimens
[29]. Lastly, Wang et al. using FFPE tissue sections from
patients, mentioned key differences in upregulation of
high-mannose glycans and in downregulation of sialylated
biantennary complex glycans [30]. Some discrepancies in
alterations demonstrated in the above-mentioned three studies
are probably due to different preparative approaches.
The main purpose of our present work was to investigate
the validity of N-glycan changes in tumor and noncancerous
tissues and discriminate differences related to disease stages
of LAC. Previously, we reported a simple preparative pro-
cedure, which enabled effective release of all N-glycan
types from freeze-dried small-sized specimens including
two patient biopsies [31]. Using this approach on non-
processed samples, we determined N-glycan profiles of
fresh tumor versus adjacent noncancerous tissues from
patients with LAC at the disease stage I–III, and evaluated
potential applicability of the data from this study to small
size biopsies procured by bronchoscopy, which usually lack
control (noncancerous) tissue samples.
Materials and methods
Lung tissue specimens
The tissue samples of patient cohorts were obtained through
surgery and bronchoscopy from the Departments of Surgery
and Respiratory Diseases and Tuberculosis, University Hos-
pital and Faculty of Medicine, Masaryk University Brno.
Tissue specimens were collected at the Department of
Pathology (University Hospital and Faculty of Medicine,
Masaryk University in Brno). All of the patients involved
signed an informed consent approved by regional Ethics
Committee. Basic demographic and clinical characteristics of
patients annotated for sex, age, smoking status and histolo-
gical results are listed in Supplementary Table 1. After gross
morphological examination of resected lung tissues from
surgery, samples were dissected from both tumor and distant
noncancerous tissues and collected separately in sterile tubes.
The size of these pieces varied between 5 and 10mm.
Depending on the total size of the resected lung portion,
healthy tissues were cut in distances 1–5 cm from tumor and
were considered as controls. To rule out a potential tumor
infiltration into adjacent control tissues, histological exam-
inations of noncancerous tissues were performed. The tubes
with fresh tissues were delivered on wet ice to the proteomics
laboratory. Larger tissues were cut with scissors into smaller
pieces (1–3mm), washed with cold PBS (3 × 300 μL) and
then with distilled water (2 × 100 μL) to remove blood. After
that, tissues were used for deglycosylation and the remaining
washed pieces were stored at −80 °C.
Biopsies with sizes varying between 1 and 5 mm were
obtained during examination of patients with a flexible
bronchoscope and flushed into physiological solution. This
solution was discarded and pieces larger than 2 mm were
cut into two smaller proportions. After washing with dis-
tilled water (3 × 100 μL), tissue was immediately used for
deglycosylation or stored at −80 °C.
N-Glycan release
Prior to deglycosylation, washed tissues were first extracted
with organic solvent as described previously [31]. Briefly,
1–2 tissue pieces with size 1–3mm were mixed with 300 µL
solution consisting of chloroform–methanol–water (8:4:1) and
sonicated for 3 min, then shortly centrifuged and supernatant
was discarded. The residue of organic solvent from tissue was
removed by evaporation under vacuum (~10min). Dried tis-
sue was resuspended in 5mM ammonium bicarbonate
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solution (AB; 80 µL) with PNGase F (2 μL, Sigma-Aldrich)
and vortexed at 37 °C for 2.5 h. The digest was purified or
incubation continued with neuraminidase (5 mU, Clostridium
perfringens, Sigma-Aldrich) at 37 °C for 2 h and then purified.
Solid phase extraction (SPE)
After a short centrifugation (~3 min), the liquid proportion
of the digest was extracted on nonporous graphitized carbon
cartridges (SupelcleanTM ENVI-Carb, 1 ml Tubes). The
cartridge was first washed with 100% acetonitrile (ACN),
90% ACN with 0.1% trifluoroacetic acid (TFA) following
deionized water (5 × 800 μL of each solvent). Supernatant
with released N-glycans was applied to the wet carrier, and
after adsorption (5 min), the cartridge was washed with
deionized water (2 × 100 μL, 5 × 600 μL) and 40% ACN
(100 μL). Oligosaccharides were eluted with a solution of
40% ACN with 0.1% TFA (1 × 200 μL and 2 × 300 μL) into
one tube and the eluate was evaporated.
Permethylation
SPE purified glycans were permethylated by applying a
procedure reported previously [32] with slight modifica-
tions. The dried glycan pool was resuspended in DMSO
(50 μL), mixed with powdered NaOH (2 mg) and MeI (15
μL). After 30 min of vortexing at room temperature, the
reaction was stopped with ice-cold water (300 μL) and
chloroform (300 μL). Chloroform portion was washed with
distilled water until the pH of the aqueous layer was neutral
and fully evaporated. Prior MS analysis permethylated
glycans were reconstituted in 70% MeOH (10 μL) and 1.5
μL was added to the DHB matrix on the MALDI target.
On-target labeling with phenylhydrazine (PHN)
SPE purified glycans in deionized water (10–80 μL)
underwent on-target derivatization with PHN as described
previously [31, 33]. Briefly, matrix (0.8 μL) consisting of 2-
aza-2-thiothymine and phenylhydrazine hydrochloride
(ATT/PHN.HCl, 2:1) with the final concentration 3% in
ACN/deionized water (1:1) was spotted on the surface of
the AnchorChip target and followed by addition of purified
glycan fraction (1.5 μL). To the wet spot, PHN labeling
reagent (0.6 μL; PHN/ACN/water in ratio 1:1:4) was added
and left to air dry (5–10 min).
Mass spectrometry (MS) and data analysis
MALDI-MS analysis was performed with UltrafleXtremeTM
mass spectrometer (Bruker, Germany) equipped with a
Smartbeam-II laser and LIFT (MS/MS) technology. All
spectra were acquired in the reflectron positive mode with
adjusted delay time and laser intensity 80%. The instrument
was first calibrated externally using peptide calibration stan-
dards and then internally on glycans of known compositions.
The spectra were obtained through the FlexControl software.
PHN labeled N-glycans were identified manually and their
structural assignment was derived from their molecular mas-
ses and MS/MS fragmentation patterns applying rules
described previously [33, 34], supported through exoglyco-
sidase digestion with β-galactosidase (bovine testes, Sigma).
Fragment ions in tandem mass spectra were assigned
according to the nomenclature described by Domon and
Costello [35]. For annotation of detected glycan peaks and
drawing their structures, the symbolic nomenclature was
applied (http://www.functionalglycomics.org).
Both qualitative and quantitative comparisons of N-glycans
were performed in non-cancerous (healthy) and tumor tissues
from surgery. First, the intensities of detected glycans were
evaluated for presence (nonzero intensity in a replicate) or
absence otherwise. The association between presence of a
glycan and sample type (tumor, healthy), sex, stage, grade,
and age was assessed by Fisher’s exact test or logistic
regression (significance threshold p < 0.05). These compar-
isons were performed in R version 3.6.1 (https://www.R-
project.org/). Secondly, the relative percentages of detected N-
glycans were calculated from their normalized intensities after
processing spectra with FlexAnalysis (Bruker) and Microsoft
Excel software. To evaluate the changes between glycans of
the same compositions, we define statistic RT/H as a ratio
between intensities of tumor and paired or representative
(averaged) noncancerous tissue of a patient. The ratio >1.3 or
<0.8 was considered significant.
Methodology applied for clinical specimens
The validity of procedure for N-glycan profiling in fresh and
defrosted tissues was evaluated by: (a) analyses of fresh
specimens excised from tumor and noncancerous tissues
(controls) from each patient subjected to surgery; and (b)
repeating glycan analyses of samples from the same patient or
a group of patients using defrosted tissue specimens, which
were stored at −80 °C. The experiments were repeated at least
three times for each tissue sample with exception of small size
biopsies (<3 mm) obtained via bronchoscopy.
Results
Patients and specimens
N-Glycans of tissue specimens from 16 patients with
diagnosis of LAC were subjected to comparative analysis.
As listed in Supplementary Table 1, the patients included in
this study were in the following disease stages and
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morphological grades (G): two patients (P1 and P2) in the
stage IA2-3 (G2), five patients (P3–P7) in the stage IB
(G1–G3), two patients (P8 and P9) in the stage IIA (G3 and
G4) and two patients (P10 and P11) in the stage IIB (both
G2), five patients (P12–16) in the stage III, four of them in
the stage IIIA (G2 and G3) and the last one in the stage IIIB
(G3). Specimen analyzed from each patient included a
tumor and a control tissue sample.
In addition, small size biopsies for glycan analyses were
obtained via bronchoscopy from eight patients (Supple-
mentary Table 1). Three of them (P17-P19) were in stage IA
(G2-G3) and one patient (P20) in stage IB (G2). In the case
of another four patients, clinical characteristics were as
follows: in case patient P21 the stage was not determined,
P22 had a chronic inflammation of lung with history of
LAC and the other two patients (P23 and P24) were in stage
IIIA-B/G3 and IV/G3, respectively.
N-Glycan profiles of noncancerous tissues of LAC
patients
The comparison of N-glycan profiles of noncancerous tis-
sues adjacent to tumor before and after desialylation showed
that the proportion of sialylated glycans represents between
60 and 70% and the rest were neutral forms. The presence
of NeuAc residue/s was validated by analysis of per-
methylated pools. Figure 1 displays relative intensities of
individual glycans in noncancerous tissues. There are 51
glycans that were detected in at least one technical replicate
in all samples (see Supplementary Table 2).
High-mannose glycans were detected in all samples and
among them only the structure with composition Man5-
GlcNAc2 (m/z 1347) was observed with higher intensity
(5–9%) than those carrying more mannoses (Man6–9
GlcNAc2; < 2%). Other than differences in higher sialylation
and a lower proportion of high-mannose glycans, our
observations of detected glycan structures are in line with
those previously reported from analyses of healthy human
lungs [36]. In desialylated pools the most prevalent N-glycan
(~45%) corresponded to the biantennary digalactosylated
core fucosylated structure (Gal2GlcNAc2Man3GlcNAc2Fuc;
m/z 1899). A similar glycan but without fucose (Gal2Glc-
NAc2Man3GlcNAc2; m/z 1753) was the second major peak
detected in all control lung tissues (~20%).
Tri and tetrantennary core fucosylated glycans (m/z 2264,
2630), and other structures consistent with multiple LacNAc
extensions (m/z 2995, 3360, 3725, 4090 etc.) were detected
in all tissue specimens. The peak intensities of these glycans
declined acquiring additional LacNAc unit. Among N-gly-
cans with more Fuc residues, complex biantennary core
fucosylated with the second fucose at antenna (Fuc1-
Gal2GlcNAc2Man3GlcNAc2Fuc; m/z 2045) was detected in
all samples with highest intensity (~0.5%).
None of the glycans was significantly differentially
detected in female than male in noncancerous tissues. Age
was not significantly associated with presence of a glycans
except for those with limited (4 out of 16) or near complete
presence (13 out of 16). These glycans combined represent
less than 1.40% (median 0.83%) of relative intensities of
controls and more than 2.44% (median 4.16%) of relative
Fig. 1 Graphical illustration of
detected N-glycans in control
tissues of patients with lung
adenocarcinoma with stage
IB–IIIB and grade 1–4. The
graph was obtained from
experiments of 16 samples,
which were deglycosylated and
analyzed separately in different
period times and represents the
averaged relative intensities with
error bars as shown (±SD).
N-glycan compositions are on
the horizontal axis (H-hexose,
N-GlcNAc, F-fucose) and their
percentage abundances are
depicted on the vertical axis.
Key symbols: Fuc (triangle), Gal
(empty circle), GlcNAc (square),
Man (circle). The top graph
shows glycans with a range of
m/z 860–1995; and the bottom
one with m/z 1995–3725. For
more data see Supplementary
Table 2.
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intensities of tumors. Glycan with m/z 3506.3 exhibited
significantly different presence in noncancerous tissues
from patients with different stage (p= 0.012). The glycan
was dectected in all patient of stage II and III but in only 2
patients of stage I. Since, there is only one sample of grade
4 and 1, only presence of glycans in grades 2 and 3 could be
evaluated. Glycan with m/z 3271.2 exhibited significantly
different presence in noncancerous tissues from patients
with different grade (p= 0.041). This glycan was detected
in one out of ten samples of grade 2 and in three out of four
samples of grade 3. Both glycans represent at most 0.12%
(P13) and 0.06% (P16) of the total intensity of individual
samples. Representative spectra of samples of different
stage and grade are shown in Supplementary Figs. 1 and 2.
Despite presence of some minor glycans in noncancerous
tissues of some subgroups of patients, comparison of N-
glycans from control tissues adjacent to LAC tumors indi-
cates that these profiles can be used as reference control data
independent of the age, sex, stage, or grade of patients.
These data could be applied in those cases when only tumor
tissues are available for analyses (Fig. 1).
N-Glycan profiles of cancerous versus healthy lung
tissues
MS analyses of N-glycans from cancerous tissues against
control specimens showed altered glycan profiles in all
patients. The extent of these alterations varied with the disease
stage and histological grade of LAC. The comparison of
profiles before and after incubation with neuraminidase
showed that the total proportion of sialylated glycans in
cancerous specimens varied in a range from 50 to 70%. An
example of recorded MALDI-MS spectra of N-glycans
released from tumor and healthy tissues after desialylation is
illustrated in Fig. 2. The results of frequent changes in N-
glycans are summarized in Supplementary Tables 2 and 3. As
shown, N-glycans compositions detected in cancerous speci-
mens were generally elevated and only some glycans (e.g., m/
z 1899) declined. Importantly, 42 new asparagine-linked oli-
gosaccharides were found exclusively or dominantly detected
in cancerous tissues. Compared with control tissues, pauci-
mannose N-glycans (Man2–4GlcNAc2) and their fucosylated
analogs (Man2–4GlcNAc2Fuc) were increased in all tumors.
The most significant change (RT/H > 3), mainly in fucosylated
paucimannose glycans, was observed in the patients P4 at
stage IB/2 and P13 and P15 at stage III (Supplementary
Table 3). Besides patient P9, high-mannose glycans with 6–9
mannose residues were increased in all cancerous tissues, Yet,
the glycan with the composition Man5GlcNAc2 (m/z 1347)
showed either no significant change or even decrease in
majority of tumors.
The major peaks in the spectra of all analyzed lung
samples after desialylation matched to the complex
biantennary digalactosylated glycans with composition
Gal2GlcNAc2Man3GlcNAc2 (m/z 1753) and a similar struc-
ture with fucose at the reducing termini—Gal2GlcNAc2-
Man3GlcNAc2Fuc (m/z 1899; e.g., Fig. 2). We observed in
all tumors a consistent decrease in this core fucosylated
glycan (RT/H~0.5–0.8), while its non-fucosylated analog
showed no systematic change (RT/H~0.7–1.3). The glycan
with composition Gal1GlcNAc3Man3GlcNAc2Fuc (m/z 1940)
showed the most prominent increase in patients P15 and
P16 at stage III (RT/H > 3). The fragmentation pattern of this
glycan recorded from tumors of patients (P1–P11) at the
disease stages I–IIB suggested a prevalence of the isomer
with a branching on the 6-antenna (Supplementary Fig. 3a).
This isomer was detected solely in all healthy tissues.
However, an increase of the structure with bisecting moiety
was observed in tumors of patients at the disease stage III
(Supplementary Fig. 3b).
Tri- and tetra-antennary galactosylated glycans with core
fucose (Gal3-4GlcNAc3-4Man3GlcNAc2Fuc; m/z 2264 and
2630) as well as corresponding structures branched or
extended by the additional N-acetyllactosamine (LacNAc)
units were detected in all samples (m/z 2995, 3360, 3725,
4090 etc). Comparing cancerous versus healthy tissue of
patients, the increase in these glycans was noticeable mostly
in the disease stage IA–IIB (RT/H ~1.3-3).
Distinctive N-glycan changes linked to disease
stages of LAC
Most consistent and significant changes in N-glycan profiles
at different disease stages were observed in the core fuco-
sylated oligosaccharides carrying additional Fuc and/or
non-galactosylated GlcNAc residues. An example of these
changes is shown in Fig. 3 (the same spectra with m/z under
3000 are in Supplementary Fig. 4). The majority of bi-, tri-,
tetra-antennary glycans with more fucoses were already
detected in tumor tissues of patients at stage I, however with
intensities mostly not sufficient for the structural analysis (s/
n < 5). The stage IIB and III differed in increased occur-
rence of these and additional new glycans (e.g., m/z 2703,
2963, 3068, 3109, 3125, 3255, 3271, 3417, 3579). Stage III
showed presence of more tetraantennary core fucosylated
structures branched with one to four GlcNAc residues
without further substitution besides fucose/s (e.g., 1924,
2273, 2435, 2451, 2719, 2760, 3474, 3928). Although
more isomers for each of these glycans were possible,
MS/MS fragmentation experiments for all of them indicated
dominancy in the core fucosylated glycans with
additional fucose and non-galactosylated GlcNAc residues
on the 6-antenna (Supplementary Fig. 5). It should be
noted, and as listed in the Supplementary Table 3, tumor
tissues of mucinous LAC exhibited more heterogeneous
profiles when compared with tumor tissues of LAC patients
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at the same disease stage. Furthermore, the N-glycan profile
of cancerous tissue obtained from the patient P5 with LAC
in the stage IB/G2 exhibited higher values and even more
heterogeneous profile when compared with other patients
with LAC (Fig. 2). This female was diagnosed with breast
cancer and underwent chemotherapy seven years ago.
Notably, the histological examination of regional lymph
nodes did not confirm a presence of metastases in the P5
patient.
Data application for profiling of biopsies
N-Glycan profiles’ data obtained from the control and can-
cerous tissue specimens of LAC described above were next
Fig. 2 MALDI-MS spectra of
N-glycans recorded from
cancerous and control lung
tissues of patient with LAC. In
a, b are shown glycans detected
in the range of m/z 860–3000;
and in c, d are glycans with the
range of m/z 2650–4150. The
analyzed tissues are from patient
P5 (IB/G2). Key symbols: Fuc
(red triangle), Gal (yellow
circle), GlcNAc (blue square),
Man (green circle) For more
peak assignments, see
Supplementary Table 3.
N-Glycan profiling of lung adenocarcinoma in patients at different stages of disease 1151
applied for evaluation of biopsies obtained during broncho-
scopy examinations (Supplementary Table 1). The biopsies
(~3mm size) of three patients (P17–P19) diagnosed with
LAC in stage IA3/G2 and G3, allowed detail analysis of all
groups of N-glycans. As depicted in Fig. 4, N-glycan profiles
of all three biopsies showed characteristics associated with
disease. However, the profile of patient P17 showed resem-
blance to a higher stage than histology (stage IA3/2).
The sizes of biopsies (~1 mm) of patients P20 with stage
IB/G2 and P21 with undetermined stage/grade allowed
detection of N-glycan with m/z under 3000. On the other
side, recorded profiles showed the presence of glycan
structures related to malignancy (Supplementary Fig. 6).
Three other patients with diagnosis of LAC were under
long-term chemotherapy and lung lesions detected in follow-up
examinations suggested potential relapse (P22, P23, and P24).
In the case of patient P22, who underwent chemotherapy two
years prior the bronchoscopy, the most noticeable alteration
was a decline in the structure with five mannoses (Man5-
GlcNAc2, m/z 1347) and biantennary digalactosylated glycan
with core fucose (Gal2GlcNAc2Man3GlcNAc2Fuc, m/z 1899).
Bi- and tri-antennary galactosylated glycans with compositions
Gal2–3GlcNAc2–3Man3GlcNAc2 (m/z 1753 and 2118) were
significantly increased (RT/H > 2; Supplementary Fig. 7). Other
N-glycans associated only with LAC as listed for example in
the Supplementary Table 3 were not detected in this biopsy.
Histological examinations revealed inflammation in this biopsy
and no morphological signs for malignancy. In the patients P23
and P24 in advanced stages of disease, MS analysis provided
consistent data on N-glycan profiles up to m/z 2600. Despite
this, N-glycan profiles exhibited some of changes typical for
higher disease stages. In the biopsy of patient P23 at the disease
Fig. 3 MALDI-MS spectra
with mass range 2650–4150.
N-Glycans were obtained from
malignant lung tissues of
patients: a P3 (IB/1); b P9
(IIA/4); and c P15 (IIIA/2). All
ions are MNa+. For more
detailed peak assignments, see
Supplementary Table 3. Glycans
detected at m/z under 3000 in the
same spectra are shown in
Supplementary Figure 4.
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stage IIIA, besides a significant increase in structures carrying
fucose residues (m/z 2045 and 2191), we observed a prominent
increase in the biantennary glycan with bisecting moiety (m/z
2102, Supplementary Fig. 8a). In the P24 patient in the disease
stage IV, a prominent increase was detected for tri and tetra
antennary core fucosylated glycans with non-galactosylated
GlcNAc residues and additional one or two fucoses on the
branches—Gal1Fuc1GlcNAc3Man3GlcNAc2Fuc (m/z 2086),
Fuc1-2GlcNAc3Man3GlcNAc2Fuc (m/z 2127, 2273; Supple-
mentary Fig. 8b). Thus, despite tissue limitations in biopsies
from bronchoscopy, the application of accumulated data from
glycan analyses of fresh/frozen tumor and control (non-
cancerous) tissues made it possible to determine the nature of
lung lesions in eight patients. The findings based on glycan
detections were in line with clinical and histopathological
diagnosis in these patients.
Discussion
We reported earlier sample preparative procedure for
investigation of N-glycans from human cells of established
cancer cell lines including those derived from LAC pre-
served by lyophilization [31]. The aim of the present study
was to investigate applicability of this method in clinical
settings for analysis of N-glycans from fresh as well as
defrosted tissues of LAC patients, and to determine poten-
tial correlations between N-glycan profiles and disease
stages of LAC. The presence of sialylated glycans carrying
NeuAc residue/s we confirmed by permethylation. How-
ever, comparative profiling we applied mainly on desialy-
lated N-glycans for two reasons: (1) some minor N-glycans
but of potential importance were conclusively recognized
only in desialylated N-glycan pools, and (2) this approach
provides benefit as a simple method for clinical utility with
a high reproducibility of glycan profiles. The comparison of
cancerous versus adjacent control tissues of LAC patients
showed significant alteration in N-glycans in dependence to
disease progressions. While noncancerous tissues of all
patients provided highly consistent resemblance in glycan
profiles (see Fig. 1) with few exceptions in relative inten-
sities of glycans present in both cancerous and healthy
tissues, a number of new N-glycans were detected in can-
cerous tissues (Supplementary Table 3). As illustrated for
example by pie charts in the Supplementary Fig. 9, the
clear-cut changes in proportion of some structures or
grouped minor N-glycans according their compositions,
were already detected in patients with LAC at stage IA and
IB, which increased in patients with advanced stages.
The previous studies of LAC patients was restricted on a
comparison of the same glycans detected in both cancerous
and control tissues [29, 30]. Both research groups reported
consistent increase in high-mannose glycans. Indeed, in our
study the glycans with 6–9 mannoses were increased in all
tumors (e.g., Fig. 2a). However, the glycan with composi-
tion Man5GlcNAc2 (m/z 1347) exhibited mostly a decrease.
Fig. 4 Graphical illustration
of detected N-glycans in the
biopsies of patients P17-19
with LAC with stage IA3/G2-3
versus profile obtained from
averaged values of control
tissues from surgery (blue
color). In a are glycans with a
range of m/z 1007–2102; and in
b with m/z 2102–3725.
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Our observation correlates with the results from recent
study focused on differential expressions of the α-1,2-
mannosidase genes [37]. The researcher reported that
mannosidase MAN1A1 overexpression increases the high-
mannose glycans with compositions Man6–9GlcNAc2 but
not Man5GlcNAc2. Furthermore, our data obtained from
analysis of control lung tissues showed that this glycan was
the most significant structure among high-mannose types,
whereas those with compositions Man6–9GlcNAc2 were
detected with much lower abundances (Fig. 1).
As described previously [29], we observed a consistent
decline in the sialylated complex biantennary core fucosylated
digalactosylated glycan in tumors, which after desialylation
was detected at m/z 1899 (Gal2GlcNAc2Man3GlcNAc2Fuc;
e.g., Supplementary Fig. 9). However, similar glycan without
fucose (m/z 1753), described also with a significant decrease
in the above-mentioned study, in our tumor tissues did not
show consistently the same change. On the contrary, in most
tumors it was even higher than in adjacent control samples. A
significant increase of this glycan was observed in one patient
(P6) at a disease stage IB/2 and two patients (P8, P9) with the
stages IIA/G3 and 4. The most significant increase was
detected also in the biopsy of the patient P22 (Supplementary
Fig. 7), suggesting its association in general with inflamma-
tion than cancer progression. It should be pointed out that
some investigators emphasized the preferences for analyzing
FFPE tissue sections instead of using fresh/frozen tissue
specimen [30]. The main objection was that fresh or frozen
tissues could contain blood, which despite thorough washing
of tissue cannot be eliminated. Surprisingly, the N-glycan
profile of samples from FFPE tissue sections in their pub-
lication shows that the main glycan normally identified in
blood (NeuAc2Gal2GlcNAc2Man3GlcNAc2) was still the most
abundant sialylated N-glycan (m/z 2792) in control FFPE
tissues of permethylated samples [30]. While earlier study
[36], as well as our present work (e.g., Figs. 1, 2b) shows the
most abundant N-glycan in control lungs following desialy-
lation corresponds to the core fucosylated type (Gal2Glc-
NAc2Man3GlcNAc2Fuc) which in serum/plasma is generally
detected with much lower abundance either before or after
desialylation.
In contrast to the previously published reports, we extended
analysis into the area of new, heterogenous and more complex
glycan structures. As demonstrated in the previous sections,
core fucosylated glycans with multiple LacNAc extensions
were detected in all spectra. These glycans dominated in mass
range over 2600Da in all control tissues and tumors with early
disease stage. The core fucosylation is catalyzed by alfa-1,6-
fucosyltransferase (FUT8) [38, 39]. The decline in the core
fucosylated glycan, regularly observed for N-glycan with a
composition Gal2GlcNAc2Man3GlcNAc2Fuc (or as NeuAc1–2
Gal2GlcNAc2Man3GlcNAc2Fuc prior to desialylation) in our
work and in previous study [29], differs from the previously
reported upregulation of FUT8 in NSCLC and metastasis [40].
On the other side, the most significant differences in early
stages were in the increase of tri and more antennary glycans
with core fucose and those carrying additional fucose/s on the
antennae (Supplementary Fig. 9). Increased arm fucosylation is
Fig. 5 Comparison of healthy
and cancerous lung tissues. In
a are shown histological cross-
sections of healthy and tumor
lung tissues obtained from
patient P9. In b is schematic
illustration of main differences
in glycosylation pathways of
complex core fucosylated N-
glycans observed between
control (blue lines) and
cancerous lung tissues (red lines;
dotted line represents decrease)
based on MS and MS/MS
analyses.
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most likely the result of upregulated α-1-3-fucosyltrasferase
(FUT3) [26]. Very lastly, it has been reported that both FUT3
and FUT6 played key roles in mediating metastasis to bone
[17]. We further observed that fucosylated glycans were often
branched with non-galactosylated GlcNAc residues, preferably
linked on the 6-antena at LAC higher stages (Supplementary
Fig. 5). It provides evidence that besides increased activities in
FUT3 and FUT6 the progression of LAC is associated also
with a higher expression of GnT-V, a glycosyltransferase that
catalyzes the formation of β-1,6-GlcNAc branches. Upregula-
tion in this enzyme has been described with malignancies as
well [16, 41]. The majority of newly detected N-glycans has
not been reported in LAC patients in earlier studies. Moreover,
20 of them are not listed in the human or animal glycan
databases. The main difference in glycosylation pathways of
the core fucosylated glycans in brief is illustrated in a scheme
of Fig. 5. These differences are derived based on identification
asparagine-linked oligosaccharides in control and cancerous
lung tissues.
Next, we tested applicability of the N-glycan data
obtained in this study for evaluation of biopsies with limited
sizes and lacking control tissues. Despite these limitations,
the detected glycans in the biopsies of patients
P17–21 showed characteristic features of malignant trans-
formation of tissue (Fig. 4 and Supplementary Fig. 6).
However, the biopsy of female (P17) in disease stage IA3/
G2, showed a more heterogeneous profile than we expected
for this stage. As mentioned in the section of Results,
among examined cancerous tissues from surgery, female in
the disease stage IB, of which MS spectra can be seen in
Fig. 2, displayed profile that was much more heterogeneous
then stage III. We did not include all the detected glycans
from her in Supplementary Tables 2 and 3 because of
patient’s diagnosis of cancer in the past. However, patient
P17 has no record any malignancy prior to LAC.
Three further patients (P22–24) were checked for a
potential relapse of LAC. The patient P22 showed an altera-
tion not characteristic for LAC (Supplementary Fig. 7), which
was confirmed by histology examinations displaying only
inflammation with no malignancy. In two other patients (P23
and P24) suspected of LAC relapse, the identified N-glycans
indicated poor prognosis (Supplementary Fig. 8). The glycans
at m/z 2086, 2127 and 2273 corresponded to the tri and tetra
antennary structures with compositions Gal1Fuc1GlcNAc3-
Man3GlcNAc2Fuc and Fuc1–2GlcNAc4Man3GlcNAc2Fuc and
were detected in high prevalence particularly in biopsy of the
patient P24 at stage IV.
In conclusion, we present a comprehensive N-glycan ana-
lysis in tissues of LAC patients. We found a clear difference
between cancerous and healthy lung tissue and the changes in
N-glycan profiles are becoming more prominent in advanced
stages (II and III) of disease. Data from comparative N-glycan
analyses of tumor tissues to controls using either from the same
patient or the reference control averaged from 16 patients
showed the same significant difference between glycan profiles
of tumors and noncancerous lung tissues. Potentially, these data
enable expeditious differentiation between LAC and non-
cancerous lung tissues including those biopsy specimens,
which lack controls. We found a number of adenocarcinoma-
related glycan structures not reported previously in tumor tis-
sues of LAC patients. The presented N-glycan database enables
more focused follow up studies on a larger patient cohort aimed
to determine potential markers in the early disease stage as well
as those associated with the early metastatic processes. More-
over, this study demonstrates high potential for the approach
used here in clinical testing. The analysis of N-glycans from
fresh tissue provides an additional opportunity for a rapid
discrimination between cancerous and healthy lung tissue. New
glycan structures might serve as promising biomarkers of
which presence in the first step of analysis indicates malignant
processes prior to carrying out more complex, however
demanding quantitative data analysis. We were able to detect
unexpected abnormalities in profiles of two patients, not con-
sistent with assigned histological stages and we observed gly-
cans characteristic of cancerous tissue from bronchoscopy in
another patient where histology was not successful. Thus, a
combination of knowledge from different methodologies might
together provide deeper insights into malignancy and its
behavior on more individual levels.
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